genomics solving the unsolvable. genomics bacterial infections genomics pathogens without borders

We are GenPAx

Game-changers in the field of genome analysis for pathogens

The ‘golden age’ of antibiotics, kick-started by Fleming’s discovery of penicillin and Florey and his colleagues’ development of penicillin and cephalosporins spanned the 1930s to the 1960s. About half of the drugs we use to fight infection today were discovered in that period. The pace of discovery has fallen since then, and we are losing the arms-race between bacterial innovation in developing resistance and human discovery and invention of new agents.


Superbugs (AMR) will kill 'more than cancer' by 2050 at cost of $100 trillion to the global economy*
*Source: CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report)


That is the tip of the iceberg – 100x larger non-resistant bacteria market


Knowing which species of bacteria is not enough, we need scalable joined-up
genomics-based diagnostics

What is our biggest challenge?

Cost of AMR to reach $100 trillion by 2050

Antimicrobial resistance is the biggest challenge we face as a human race with a global economic cost of over $100 trillion by 2050, and annual-associated deaths that will exceed cancer, according to WHO. Once treatable infections will become increasingly impossible and unaffordable to control, and once safe hospital procedures will become life-threatening.

Bacterial threat beyond the point of control

It is essential that new and emergent bacterial threats can be effectively identified and controlled in hospital settings, as well as in animals, food, and the environment. The COVID-19 / SARS-CoV-2 pandemic highlights how imperative it is that an outbreak is not allowed to grow beyond the point of control. This is exactly the situation we face with AMR.

What is the solution?

Joined-up, genomics-based diagnostics

It is critical that analysis for high-resolution diagnostics is able to distinguish individual challenging strains of bacteria to the diagnostic front-line and that we improve our ability to co-ordinate responses. We need scalable, joined-up, genomics-based diagnostics that can inform infection control and effective responses in real clinical time and to create our own network to enable this.

Sign up for free to join our community

GenPAx has a team of world class bioinformaticians developing new technology to detect outbreaks and tools to enable collaboration when they occur. We are looking for colleagues and partners to join us on this journey.

Latest blogs from GenPAx

When will someone call laST orders?
Nigel SaundersSeptember 20, 2021 | 4 weeks ago

When will someone call laST orders?

Sequence Typing (ST) is a widely established and ...
What is the larger threat of hospital-associated infection?
Nigel SaundersJuly 14, 2021 | 3 months ago

What is the larger threat of hospital-associated infection?

COVID-19 is not the pandemic I was predicting. ...
Is AMR really a product of misuse and abuse by doctors?
Nigel SaundersJune 5, 2021 | 4 weeks ago

Is AMR really a product of misuse and abuse by doctors?

It is repeatedly stated that we face a global ...

Latest blog from GenPAx

When will someone call laST orders?
Nigel SaundersSeptember 20, 2021 | 4 weeks ago

When will someone call laST orders?

Sequence Typing (ST) is a widely established and ...

Send a message





    please, sign me up to your free newsletter

    We’d love to keep you updated with our latest news and offers

    Subscribe to our blog

    Shannon Rapp

    VP, Finance & HR

    Shannon Rapp's expertise in Finance and HR spans 30 years across a wide-range of industries. She specializes in growing start-up companies from infrastructure to culture. She excels at keeping companies focused to ensure both their strategic and organic development. Shannon is renowned for her extensive accounting experience, audit experience, and energetic drive.

    When she's not helping companies successfully grow, Shannon spends her time scuba diving, practicing yoga, and walking her dogs on the beach.

    Ray Schaaf

    President, Inc.

    Ray has over 30 years of experience spanning digital content, wireless, and e-commerce industries where he has held numerous executive positions managing companies in the USA, Asia, and Europe. He focuses on building successful companies with high quality teams that deliver creative products and services to the market.
    Passions: skiing and hiking

    Shannon Rapp

    VP, Finance & HR

    Shannon Rapp's expertise in Finance and HR spans 30 years across a wide-range of industries. She specializes in growing start-up companies from infrastructure to culture. She excels at keeping companies focused to ensure both their strategic and organic development. Shannon is renowned for her extensive accounting experience, audit experience, and energetic drive.

    When she's not helping companies successfully grow, Shannon spends her time scuba diving, practicing yoga, and walking her dogs on the beach.

    Julian Hardy

    CEO

    Julian Hardy is a serial entrepreneur with a proven track record of rapidly forming and building companies to the point product and revenue delivery. He’s been at the forefront of a number of innovative high growth technology sectors: mobile gaming, IoT, crypto and, Biotech. Bringing highly differentiated solutions to market, executing on a big vision. Julian’s strategic nature, energy, and communication skills make him a standout leader.

    Father of 6, Julian is also a highly competitive cyclist and keen snowboarder.

    Nigel Saunders

    CSO

    Nigel is an expert in clinical bacteriology and genomics. Most recently Interdisciplinary (Bioscience, Computer Science, & Maths) Professor of Systems Biology at Brunel University London, he was formerly head of the Bacterial Pathogenesis and Functional Genomics Group, at the Dunn School of Pathology, and Wellcome Fellow in Medical Microbiology at the Institute of Molecular Medicine, Oxford University. At Oxford he was also a Founding Manager of the Computational Biology Research Group.

    Notable achievements include changing the use/monitoring of vancomycin antibiotics, contributions to the sequencing project underpinning the BEXSERO vaccine, and pioneering work in microarray comparative and functional genomics.

    Nigel is also fully trained yoga instructor and runs classes out of his home studio in Devon.

    [contact-form-7 404 "Not Found"]

    [email-subscribers-form id="2"]

    Home box

    CSO

    Nigel is an expert in clinical bacteriology and genomics. Most recently Interdisciplinary (Bioscience, Computer Science, & Maths) Professor of Systems Biology at Brunel University London, he was formerly head of the Bacterial Pathogenesis and Functional Genomics Group, at the Dunn School of Pathology, and Wellcome Fellow in Medical Microbiology at the Institute of Molecular Medicine, Oxford University. At Oxford he was also a Founding Manager of the Computational Biology Research Group.

    Notable achievements include changing the use/monitoring of vancomycin antibiotics, contributions to the sequencing project underpinning the BEXSERO vaccine, and pioneering work in microarray comparative and functional genomics.

    Nigel is also fully trained yoga instructor and runs classes out of his home studio in Devon.